Evidence map›Paper›PMID 37506692›Full record

ArticleAmerican journal of human genetics2023

Population screening shows risk of inherited cancer and familial hypercholesterolemia in Oregon.

Timothy D O'Brien, Amiee B Potter, Catherine C Driscoll, Gregory Goh, John H Letaw, Sarah McCabe, Jane Thanner, Arpita Kulkarni, Rossana Wong, Samuel Medica and 24 more

Open access · bronzeAbstract read
In one paragraph

Article in American journal of human genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 3 institutions in 1 country.

Timothy D O'BrienKnight Diagnostic Laboratories, Oregon Health & Science University, Portland, OR 97239, USA.
Amiee B PotterKnight Diagnostic Laboratories, Oregon Health & Science University, Portland, OR 97239, USA.
Catherine C DriscollKnight Diagnostic Laboratories, Oregon Health & Science University, Portland, OR 97239, USA; Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97201, USA.
Gregory GohKnight Diagnostic Laboratories, Oregon Health & Science University, Portland, OR 97239, USA; Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97201, USA.
John H LetawKnight Diagnostic Laboratories, Oregon Health & Science University, Portland, OR 97239, USA.
Sarah McCabeKnight Diagnostic Laboratories, Oregon Health & Science University, Portland, OR 97239, USA.
Jane ThannerInformation Technology Group, Oregon Health & Science University, Portland, OR 97201, USA.
Arpita KulkarniKnight Diagnostic Laboratories, Oregon Health & Science University, Portland, OR 97239, USA.
Rossana WongKnight Diagnostic Laboratories, Oregon Health & Science University, Portland, OR 97239, USA.
Samuel MedicaIntegrated Genomics Laboratory, Oregon Health & Science University, Portland, OR 97239, USA.
Tiana WeekIntegrated Genomics Laboratory, Oregon Health & Science University, Portland, OR 97239, USA.
Jacob BuitragoIntegrated Genomics Laboratory, Oregon Health & Science University, Portland, OR 97239, USA.
Aaron LarsonIntegrated Genomics Laboratory, Oregon Health & Science University, Portland, OR 97239, USA.
Katie Johnson CamachoCancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97201, USA.
Kim BrownKnight Cancer Institute, Community Outreach and Engagement, Oregon Health & Science University, Portland, OR 97201, USA.
Rachel CristKnight Cancer Institute, Community Outreach and Engagement, Oregon Health & Science University, Portland, OR 97201, USA.
Casey ConradCancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97201, USA.
Sara Evans-DutsonCancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97201, USA.
Ryan LutzKnight Cancer Institute, Community Outreach and Engagement, Oregon Health & Science University, Portland, OR 97201, USA.
Asia MitchellCancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97201, USA.
Pavana AnurCancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97201, USA.
Vanessa SerratoKnight Cancer Institute, Community Outreach and Engagement, Oregon Health & Science University, Portland, OR 97201, USA.
Autumn ShaferUniversity of Oregon, School of Journalism and Communication, Portland, OR 97209, USA.
Lisa K MarriottOHSU-PSU School of Public Health, Portland, OR 97239, USA.
K J HammanDepartment of Molecular & Medical Genetics, Oregon Health & Science University, Portland, OR 97239, USA.
Amelia MulfordDepartment of Molecular & Medical Genetics, Oregon Health & Science University, Portland, OR 97239, USA.
Wojciech WiszniewskiDepartment of Molecular & Medical Genetics, Oregon Health & Science University, Portland, OR 97239, USA.
Jone E SampsonDepartment of Molecular & Medical Genetics, Oregon Health & Science University, Portland, OR 97239, USA.
Andrew AdeyCancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97201, USA; Department of Molecular & Medical Genetics, Oregon Health & Science University, Portland, OR 97239, USA.
Brian J O'RoakDepartment of Molecular & Medical Genetics, Oregon Health & Science University, Portland, OR 97239, USA.
Christina A HarringtonIntegrated Genomics Laboratory, Oregon Health & Science University, Portland, OR 97239, USA; Department of Molecular & Medical Genetics, Oregon Health & Science University, Portland, OR 97239, USA.
Jackilen ShannonKnight Cancer Institute, Community Outreach and Engagement, Oregon Health & Science University, Portland, OR 97201, USA; Division of Oncological Sciences, Oregon Health & Science University, Portland, OR 97239, USA.
Paul T SpellmanCancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97201, USA; Department of Molecular & Medical Genetics, Oregon Health & Science University, Portland, OR 97239, USA.
C Sue RichardsKnight Diagnostic Laboratories, Oregon Health & Science University, Portland, OR 97239, USA; Department of Molecular & Medical Genetics, Oregon Health & Science University, Portland, OR 97239, USA. Electronic address: richarsu@ohsu.edu.
Oregon Health & Science University · USUniversity of Oregon · USUniversity of Portland · US

Funding

Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)UL1TR002369 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Cynthia D Morris, Christopher G. Slatore · 2017 to 2026
$78.4M
OREGON CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024140 · NCRR · OREGON HEALTH & SCIENCE UNIVERSITY · PI ORWOLL, ERIC S. · 2006 to 2011
$61.1M
Understanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Luiz Eduardo Bertassoni · 1997 to 2026
$60.5M
Measuring Gender in the Healthy Oregon ProjectU01CA232819 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI SHANNON, JACKILEN, SPELLMAN, PAUL T. · 2020 to 2023
$6.3M
Teacher Institute for the Experience of ScienceR25RR020443 · NCRR · OREGON HEALTH & SCIENCE UNIVERSITY · PI CAMERON, WILLIAM E. · 2005 to 2010
$1.6M
STEM Assessment and Reporting Tracker (START): Professional portfolio mentoring to support workforce training and longitudinal outcomes researchR25GM129840 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI MARRIOTT, LISA K · 2018 to 2022
$1.3M
CHIDR Chatter: Translating community research data forclassroom useR25OD010496 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI MARRIOTT, LISA K · 2012 to 2016
$1.3M
How sure are you? Science, Biostatistics and Cancer EducationR25RR026008 · NCRR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MOLINARO, MARCO · 2009 to 2011
$853k
NCATS NIH HHS UL1 TR002369NCI NIH HHS P30 CA069533NCI NIH HHS U01 CA232819NCRR NIH HHS R25 RR020443NCRR NIH HHS R25 RR026008NCRR NIH HHS UL1 RR024140NIGMS NIH HHS R25 GM129840NIH HHS R25 OD010496
6 · The paper itself

Abstract

The Healthy Oregon Project (HOP) is a statewide effort that aims to build a large research repository and influence the health of Oregonians through providing no-cost genetic screening to participants for a next-generation sequencing 32-gene panel comprising genes related to inherited cancers and familial hypercholesterolemia. This type of unbiased population screening can detect at-risk individuals who may otherwise be missed by conventional medical approaches. However, challenges exist for this type of high-throughput testing in an academic setting, including developing a low-cost high-efficiency test and scaling up the clinical laboratory for processing large numbers of samples. Modifications to our academic clinical laboratory including efficient test design, robotics, and a streamlined analysis approach increased our ability to test more than 1,000 samples per month for HOP using only one dedicated HOP laboratory technologist. Additionally, enrollment using a HIPAA-compliant smartphone app and sample collection using mouthwash increased efficiency and reduced cost. Here, we present our experience three years into HOP and discuss the lessons learned, including our successes, challenges, opportunities, and future directions, as well as the genetic screening results for the first 13,670 participants tested. Overall, we have identified 730 pathogenic/likely pathogenic variants in 710 participants in 24 of the 32 genes on the panel. The carrier rate for pathogenic/likely pathogenic variants in the inherited cancer genes on the panel for an unselected population was 5.0% and for familial hypercholesterolemia was 0.3%. Our laboratory experience described here may provide a useful model for population screening projects in other states.

Indexed as

Hyperlipoproteinemia Type IINeoplasmsEarly Detection of CancerGenetic TestingHumansOregonclinical genetic testingfamilial hypercholesterolemiainherited cancerlaboratory geneticspopulation screening

Identifiers

PMID37506692
PMCPMC10432140
OpenAlexW4385358772

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.